Suppr超能文献

羟氯喹、伊维菌素和阿奇霉素药物在抗击新冠病毒中的潜在用途:趋势、范围及相关性

Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.

作者信息

Choudhary R, Sharma A K

机构信息

Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana Ambala Haryana, India.

出版信息

New Microbes New Infect. 2020 Apr 22;35:100684. doi: 10.1016/j.nmni.2020.100684. eCollection 2020 May.

Abstract

Alarming situation has been caused due to the emergence of COVID-19 infection around the world. There is an urgency of developing a therapeutic strategy in order to control the spread of COVID-19. Towards that initiative, potential drugs like hydroxychloroquine, ivermectin and azithromycin have been tested by diverse group of researchers worldwide for their potential against novel coronavirus. The present report presents together the comprehensive knowledge derived from the major researches about the above drugs altogether in context of the current health emergency around the world. Hydroxychloroquine and ivermectin were known to act by creating the acidic environment and inhibiting the importin (IMPα/β1) mediated viral import. Azithromycin was found to act similar to the hydroxychloroquine as an acidotropic lipophilic weak base. All the three categories of drugs seemed to potentially act against novel coronavirus infection. However, their efficacies need to be studied in detail individually and in combination in-vivo in order to combat COVID-19 infection.

摘要

新型冠状病毒肺炎(COVID-19)感染在全球的出现引发了令人担忧的局面。为了控制COVID-19的传播,迫切需要制定一种治疗策略。为此,羟氯喹、伊维菌素和阿奇霉素等潜在药物已被世界各地的不同研究团队测试其对抗新型冠状病毒的潜力。本报告结合了世界各地当前卫生紧急情况下,来自主要研究的关于上述药物的全面知识。已知羟氯喹和伊维菌素通过创造酸性环境和抑制输入蛋白(IMPα/β1)介导的病毒输入发挥作用。发现阿奇霉素作为一种亲酸性亲脂性弱碱,其作用与羟氯喹相似。所有这三类药物似乎都有可能对抗新型冠状病毒感染。然而,为了对抗COVID-19感染,需要分别详细研究它们的疗效以及体内联合使用时的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd0/7201184/e626c010055e/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验